A three-dimensional electrospun nanofiber scaffold for use in repairing a defect in a tissue substrate is provided. The three-dimensional electrospun nanofiber scaffold includes a first layer formed by a first plurality of electrospun polymeric fibers and a second layer formed by a second plurality of electrospun polymeric fibers. The second layer is coupled to the first layer using a coupling process and includes a plurality of varying densities formed by the second plurality of electrospun polymeric fibers. The first and second layers are configured to degrade via hydrolysis after at least one of a predetermined time or an environmental condition. The three-dimensional electrospun nanofiber scaffold is configured to be applied to the tissue substrate containing the defect.

The present invention is directed to a nerve regeneration conduit including a resorbable tube having a matrix therein. The matrix is characterized by substantially parallel, axially aligned pores extending the length of the matrix. The matrix is formed by the axial freezing of a slurry having little or no significant radial thermal gradient during the freezing process. The matrix is used to bridge the gap between the severed ends of a nerve and provide a scaffold for nerve regeneration.

One aspect of the invention provides a three-dimensional scaffold including at least one layer of highly-aligned fibers. The at least one layer of highly-aligned fibers is curved in a direction substantially perpendicular to a general direction of the fibers. Another aspect of the invention provides a method for fabricating a three-dimensional scaffold. The method includes: electro spinning a plurality of fibers to produce at least one layer of highly-aligned fibers and forming the at least one layer of highly-aligned fibers into a three-dimensional scaffold without disturbing the alignment of the highly-aligned polymer fibers. A further aspect of the invention provides methods for using a three-dimensional scaffold to treat nerve or spinal cord injury.

Implantable devices for spinal cord and peripheral nerve injury are described. The implants include a three-dimensional printed structure having stem cells disposed therein. Also disclosed are methods of treating neuronal injuries with the disclosed implants.

A composition comprising Polyhydroxyurethanes, Glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines of glycosaminoglycans, chemically modified or not and a Protein or a peptide; said protein being collagen, elastin, keratin, fibronectin, actin, myosin, laminin, a peptide or a blend of those proteins or peptides, fibrillated, hydrolysed, chemically modified or not. This homogenous composition is obtained by the polymerisation or the covalent bounding of two preparations containing cyclic polycarbonates, polyamines, glycosaminoglycans, hydrolysed glycosaminoglycans, glycosamines, chemically modified or not and proteins or peptides or a blend of those proteins or peptides, fibrillated, hydrolysed, chemically modified or not.

This invention relates to biodegradable implants comprising a hydrogel carrier matrix having dispersed therein a multitude of particles, wherein each of the multitude of particles and/or the hydrogel carrier matrix includes an active pharmaceutical ingredient (API) for the treatment of transected peripheral nerve injuries. Each of the multitude of particles and/or the hydrogel carrier matrix includes pristine polymer particles, preferably the pristine polymer particles may be polymethylmethacrylate polymers and derivatives thereof, preferably poly(methacrylic-co-methyl methacrylate) (PMMA). The spheroidal particles may each be formed from an outer shell including a chitosan (CHT) poly(methacrylic-co-methyl methacrylate) (PMMA) polyelectrolyte complex (CHT-PMMA-PEC) and an inner core including crosslinked chitosan having dispersed therein PMMA nanoparticles.

The present disclosure describes compositions and methods to promote wound healing. The compositions and methods include an interleukin-1 beta (IL-1B) receptor antagonist (IL-1Ra), such as anakinra.

The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonsists, STAT3 activators, and an agent that increase nitric oxide, alone or in combination, to treat nerve deficit conditions.

The present disclosure provides a method and a kit for inducing growth or regeneration of a damaged nerve of a subject, or the treatment thereof by applying a clot of blood that is withdrawn from the subject. The blood that is withdrawn from the subject is introduced to a lumen of a nerve enveloping hollow element that envelopes the damaged portion of the nerve while controllably coagulating within the lumen to form a clot on the damaged portion of the nerve. The clot, while in physical contact with the damaged portion of the nerve, enhances the rehabilitation of the nerve and may partially or fully restore its functionality.

Tissue grafts with reduced regenerative potential, methods of preparing such grafts, and related kits and methods of treatment are described. The method may include treating tissue with a digestion solution comprising trypsin, alpha-chymotrypsin (ACT) and optionally ethylenediaminetetraacetic acid (EDTA) to substantially remove one or more susceptible proteins from the tissue. The method may also include washing the treated tissue with a buffer solution and/or with a serine-containing serum. Nerve grafts prepared according to the disclosed methods may inhibit, or lessen (e.g., provide for reduced) neuroma formation and/or axonal outgrowth after implantation.